N/A
Completed N=30
The Effect of Per Oral Immunotherapy in Severe Milk, Peanut and Egg Allergy in Adults
Source: ClinicalTrials.gov NCT03361072 ↗Enrolled (actual)
30
Serious AEs
20.0%
Results posted
May 2025
Primary outcomePrimary: Desensitisation — 7; 5; 2 Participants
Summary
The aim is to analyse the results of per oral immunotherapy treatment in severe milk, peanut or egg allergy in adults. This is the second part of the oral immunotherapy study in adults at Skin and Allergy Hospital. The diagnosis of food allergy is verified with positive history, skin prick tests, egg and milk allergen specific IgE (immunoglobulin E) antibodies. In addition, food allergy is verified with an open label (milk allergy) or blind (peanut and egg allergy) allergen specific challenge test. OIT (oral immunotherapy) is performed according to a detailed plan. Lung function parameters are followed before OIT and and a year after OIT.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Desensitisation |
7; 5; 2 | — |
| SECONDARY Worries Associated With Food Allergy |
77.7; 69.7; 61.0; 79.00; 39.5; 25.0 | — |
Eligibility Criteria
Inclusion Criteria
- severe milk, peanut or egg allergy verified with positive symptom history, skin prick tests and serum IgE tests and a challenge test
Exclusion Criteria
- instable cerebrovascular or heart disease, active autoimmune disease or cancer, or current use of betablockers.
- poorly controlled asthma or FEV1 < 70% (FEV1< -2SD)
Data sourced from ClinicalTrials.gov (NCT03361072). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.